XTLB
XTL Biopharmaceuticals
XTLB
XTLB
3 hedge funds and large institutions have $97K invested in XTL Biopharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$15K |
Top Sellers
| 1 |
SM
1
Sabby Management
Miami Beach,
Florida
|
$0 |
| 2 |
2
Invesco
Atlanta,
Georgia
|
$68K |
| 3 |
3
Citadel Advisors
Miami,
Florida
|
$0 |
| 4 |
4
UBS Group
Zurich,
Switzerland
|
$14K |
| Name | Market Value | Shares |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Invesco
Atlanta,
Georgia
| $68K | 25,961 | -103,850 | -80% |
|
|
2
Morgan Stanley
New York
| $15K | 5,560 | +2,160 | +64% |
|
|
3
UBS Group
Zurich,
Switzerland
| $14K | 5,320 | -11,620 | -69% |
|
|
SM
4
Sabby Management
Miami Beach,
Florida
| – | – | -724,134 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | – | -83,175 | Closed |
|